Kornimate/medical-research-clean huggingface dataset:
ultra violet-c light evaluation as an adjunct to removing multi-drug resistant organisms (uvclear-mdro)

Conditions: Healthcare Associated Infection; Multidrug Resistant Organisms

Summary: this study examines the impact of uv-c light disinfection as an adjunct to routine daily and discharge patient room cleaning on patient infection and colonization with hospital associated bacteria. patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. total of 83 rooms.

effective cleaning of the patient environment (the patient room during hospital stay) is subject to human factors and unfortunately is often inconsistent or inadequate. patient rooms that have residual bacteria after routine environmental cleaning can act as reservoirs for multidrug-resistant organisms (mdros) and contribute to the spread of mdros from patient to patient. in the setting of an increased focus on healthcare-associated infections such as clostridium difficile (c. difficile) and multidrug-resistant gram negative and gram positive organisms such as carbapenem-resistant enterobacteriaceae (cre), vancomycin-resistant enterococcus (vre) and methicillin-resistant staphlococcus aureus (mrsa), ultra-violet c (uv-c) light has been shown to be a safe, effective way to decrease the burden of mdros in patient rooms. however, studies examining the effectiveness of uv-c light when used post daily and discharge patient room cleaning are lacking. this study is a cluster, randomized, two-period cross over trial to investigate the relationship between environmental decontamination with uv-c light and transmission of vre and other healthcare-associated bacteria. it investigates the hypothesis that uv-c in addition to daily cleaning leads to decreased patient acquisition of healthcare-associated bacteria. this study is important to further advance hospital-based infection prevention knowledge of the impact of uv-c light for environmental cleaning. patient rooms are counted as enrolled since consent was waived and the number of participants is unknown. total of 83 rooms.

Eligibility criteria:
inclusion criteria: * patient rooms in pre-selected hospital units within johns hopkins hospital exclusion criteria: * none, intervention is at level of the hospital unit, not the patient
assessment of low level laser therapy effect on treatment outcomes of bony supported distal jet for correction of angle class ii malocclusion (randomized clinical trial)

Conditions: This Study Focus on the Effect of Low-Level Light Therapy on the Amount of Upper Molar Distalization

Summary: the goal of this randomized clinical trial is to compare the effect of lllt in adolescent patient with class ii malocclusion. the main question it aims to answer is: • is there a difference in the amount of distalization between laser and control groups? participants will received bony supported distal jet. researchers will compare laser group with control group to see if there is a difference in amount of distalization between groups.

the aim of the present study is to assess the effect of low level laser therapy on treatment outcomes of bony supported distal jet for correction of 20 orthodontic patients with angle class ii malocclusion. enrolled patient is randomly divided into 2 groups laser group and distal screw group. for result assessment dental casts and cbct are taken before and after completion of distalization. both groups receives distal jet supported on 2 paramedian screw with laser therapy for laser group only.

Eligibility criteria:
inclusion criteria: * bilateral angle's class ii malocclusion minimum of 1/4 cusp discrepancy, normal or low mandibular plane (mp) angle cases and no history of serious medical illness exclusion criteria: * subjects with skeletal class ii with retrusion mandibular profile, vertical growth pattern and steep mandibular plane angle and subjects with shallow or anterior open bite.
spectra; an observational study of the verification of protein biomarkers in transient ischemic attack.

Conditions: TIA

Summary: a multi-protein test using mass spectrometry (ms) for multiplexed protein quantitation is being developed. this test and the accompanying decision-aid software will provide transient ischemic attack (tia) results rapidly for a fraction of the price of neuroimaging. with guidance provided by this test, emergency department (ed) physicians can manage medical imaging questions such as the use of computed tomography angiography (cta) prior to ed discharge and appropriate (timely) referral to stroke clinics for consultation and follow-up care. the right patients will receive the right treatment, reduce unwarranted imaging risks and costs, and reduce the burden of stroke.

this study represents an initial verification study, in which mass spectrometry will be used to quantify a large number of blood proteins previously implicated in acvs and mimic conditions in patients who are consented and enrolled in the emergency department within 24 hrs of symptom onset. 560 patients will be enrolled, and grouped into two cohorts (cohort 1a: 220; and cohort 1b: 350). in cohort 1a, each consented participant provides three blood samples: on arrival, 4-6 hours later, then \~24 hours after that, but no later than 32 hours from symptom onset. in cohort 1b, each patient provides only a single blood sample up to 24 hours from symptom onset. a positive diffusion-weighted imaging (dwi) signal on magnetic resonance imaging (mri) or definite ischemia on computed tomography (ct) or vascular occlusion on cta will be used as proof of ischemia to classify the clinical phenotype into three groups (see below). a neurologist will adjudicate all cases according to a study defined adjudication protocol.

Eligibility criteria:
inclusion criteria: 1. age 19 and older 2. suspected tia (as per \<4 nihss; or ed physician referral to stroke clinic; 3. english speaking or translator available 4. competent to provide consent and report symptoms 5. provides at least one blood sample for the study within 24 hours after symptom onset * if three blood samples, then the patient is included in the verification study 1 cohort a. * if one blood sample, then patient is included in the verification study 1 cohort b. exclusion criteria: 1. stroke requiring admission to hospital based on only clinical observations (including ct scan) made before the mri. 2. unable to have mri/ct 3. subject unable to provide consent. 4. isolated monocular blindness.
effects of soy consumption on symptoms of menopause

Conditions: Menopause

Summary: the purpose of this study is to examine the way soy consumption affects menopausal symptoms in middle-aged japanese women.

for the past 20 years, japanese women have reported fewer menopausal symptoms than their north american counterparts. one explanation for the disparity is the differences in diet. evidence suggests that japanese women consume large amounts of soy, a phytoestrogen that is structurally similar to the hormone estrogen. however, there is a lack of menopause-related research data from non-western populations. this study will be a long-term observation of the effects of soy consumption in menopausal japanese women. this study will last 6 months. participants will complete a dietary log and a menopausal symptom checklist daily. there will be three or four study visits. during these visits, participants will complete a diet questionnaire, have a blood sample collected, and be interviewed about their menopausal symptoms. six months after study completion, participants will be sent a questionnaire about any recent menopausal symptoms they may have experienced.

Eligibility criteria:
inclusion criteria: * japanese resident * menopausal exclusion criteria: * hysterectomy, removal of ovaries, or tubal ligation with subsequent menstrual changes * hormones for menopause or birth control pills within 5 years of study entry * recent major illness * medication that could affect naturally-produced hormones

Keywords: women soy foods middle aged
the relationship with mad honey containing grayanotoxin and ovary tissue

Conditions: Ovary Disease

Summary: for our working group, eighteen healthy sprague-dawley female rats were recruited and separated into three groups in an experimental animal laboratory. group 1 was given mad honey (n:6) (80 mg/kg); group 2 was given normal honey (n:6) (80 mg/kg), and group 3 was the control group (n:6). the groups were given normal and mad honey by oral gavage for 30 days in this study. rats were anesthetized intramuscularly with 50 mg/kg ketamine and 5 mg/kg xylazine on the 30th day of the study. at the conclusion of the study, female rats in the proestrus phase of the estrous cycle (as indicated by vaginal smear) were sacrificed and their ovarian tissues were placed in neutral formalin solution.

honey poisoning is caused by consuming honey produced by bees that feed on rhododendron family plants. rhododendron poisoning goes by names such as mad honey poisoning or grayanotoxin poisoning. the purpose of this study is to determine the effects of grayanotoxin in mad honey on ovarian tissue folliculogenesis in terms of cell death and nitric oxide expression. three groups of 18 female sprague-dawley rats were formed. the first group received mad honey (80 mg/kg), the second group received normal honey (80 mg/kg), and the third group is control. the first and second groups received normal and mad honey by oral gavage for 30 days before being sacrificed under anesthesia the caspase 3 immunostaining group observed a moderate to a strong response, particularly in the granulosa cells of the graaf follicles in the mad honey group, while the normal honey and control groups observed a weak to moderate reaction. in the mad honey group, immunostaining for caspase8 and caspase 9 revealed a moderate immunoreaction in the granulosa cells of the graaf follicles, while expression was weak in the normal honey and control groups. the tunel approach revealed that the majority of graaf follicles that exhibited tunel positive in the mad honey group and progressed to atresia were graaf follicles. the inos immunoreaction revealed a high level of expression in the mad honey group, particularly in several graaf follicles. in all three groups, a weak reactivity to enos immunostaining was seen in both graaf follicles and theca external layers. according to the findings of apoptotic and nitric oxide marker expression, it was determined that mad honey may result in an increase in follicular atresia in ovarian follicles when compared to normal honey and control groups.

Eligibility criteria:
inclusion criteria: * healthy rats exclusion criteria: * patient rats * not eating rats

Keywords: grayonotoxin; mad honey; normal honey; ovary
utility of regadenoson low-dose dynamic computed tomography for myocardial perfusion assesment (ulysses study).

Conditions: Myocardial Perfusion Imaging; Computed Tomography; Coronary Artery Disease

Summary: the ulysses study is a single-center, prospective study aimed at evaluation of myocardial ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion imaging (ctp) in patients diagnosed with intermediate coronary artery stenoses in referrence to the magnetic resonance myocardial perfusion imaging (mr mpi).

the ulysses study is a single-center, prospective study aimed at evaluation of myocardial ischemia using regadenoson low-dose dynamic computed tomography myocardial perfusion (ctp) in patients diagnosed with intermediate coronary artery stenoses in referrence to the magnetic resonance myocardial perfusion imaging (mr mpi). the main objectives of the study are: * to evaluate feasibility of low - dose regadenoson dynamic computed tomography myocardial imaging protocol * to assess the diagnostic value of quantitative dynamic ctp based absolute parameters (myocardial blood flow - mbf, myocardial blood volume - mbv, perfused capillary blood volume - pcbv, peak value - pv, time to peak - ttp) in reference to magnetic resonance myocardial perfusion imaging * to assess the diagnostic value of quantitative dynamic ctp based relative parameters (relative myocardial blood flow - mbfr, relative myocardial blood volume - mbvr, relative perfused capillary blood volume - pcbvr, relative peak value - pvr, relative time to peak - ttpr) in reference to magnetic resonance myocardial perfusion imaging * evaluation of safety of regadenoson low-dose dynamic ctp.

Eligibility criteria:
inclusion criteria: * age over 18 years * signing written, informed consent by the patient for participation in the study * patients who are asymptomatic or with symptoms of stable coronary heart disease * intermediate coronary artery stenosis of at least one coronary artery in ctca exclusion criteria: * the symptoms of unstable ischemic heart disease and /or myocardial infarction, * the history of myocardial infarction * patients with impaired renal function (gfr \<60 ml) * contraindications for computed tomography or magnetic resonance imaging (including pregnancy, the presence of a cardiac pacemaker or cardioverter-defibrillator, claustrophobia, the presence of metal elements, etc.); * contraindications to the administration of iodine contrast media (including allergy to contrast, unstable hyperthyroidism, etc.) * contraindications to administration of regadenosone (hypersensitivity to the active substance, second or third degree atrioventricular block or other sinus node dysfunction, unstable angina, hypotension, decompensated heart failure, etc.); * heart failure with impaired left ventricular systolic function * a significant valvular heart disease * presence of aortic aneurysm or aortic dissection * persistent atrial fibrillation / atrial flutter * hypertrophic cardiomyopathy

Keywords: myocardial perfusion imaging computed tomography perfusion regadenoson dynamic perfusion coronary artery disease
clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of leucostim® compared to neupogen®

Conditions: Leucocytosis

Summary: bcd-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of single-injection of leucostim® to healthy volunteers compared to neupogen®


Eligibility criteria:
inclusion criteria: * written informed consent. * male gender. * age between 18 and 45 years. * normal body mass index. * verified diagnosis "healthy", established according to the anamnesis, physical examination and laboratory findings. * absence of alcohol or drug abuse. exclusion criteria: * history of use of filgrastim. * allergy to any components of study drugs. * acute hemorrhage, donation of blood / plasma or blood transfusions during last 2 months prior to enrollment in the study, history of chronic bleeding. * surgical interventions during last 30 days prior to screening or planed surgical intervention during the study. * any diseases that could interfere with pharmacokinetics of filgrastim, including chronic liver, liver or blood diseases, diseases of cardiovascular, lung and neuroendocrine systems. * fever with body temperature higher than 40°с.

Keywords: neutrophil count filgrastim granulocyte colony-stimulating factor
stress echocardiography in patients recovery from mild covid-19 illness

Conditions: Echocardiography, Stress; COVID-19; Hypertension, Pulmonary

Summary: with the appearance of the new sars-cov2 virus, additional challenges are being imposed on the medical community after the resolution of acute covid-19 illness, resulting in specific pathophysiologic mechanisms that while acutely damage the lung parenchyma might chronically impact the cardiopulmonary system. this study aims to investigate changes after mild covid-19 illness in echocardiographic indices at rest and stress.


Eligibility criteria:
inclusion criteria: * having suffered mild covid-19 illness * pcr test negative after covid-19 illness * men or women * age ≥18 years and \< 45. * no history of other cardiovascular or lung disease. * no cardiovascular risk factors, that is, arterial systemic hypertension, smoking, diabetes, dyslipidemia * no ongoing or previous cardio or vasoactive treatment * able to use the semi-supine exercise bicycle * able to give informed consent exclusion criteria: * poor acoustic window. * tricuspid regurgitation more than mild * professional sports activity * pregnancy * obesity (body mass index \[bmi\], ≥30 kg/m2). * inability to provide consent

Keywords: echocardiography, stress covid-19 pulmonary hypertension
partial lacrimal punctual occlusion

Conditions: Dry Eye

Summary: the purpose of this study is to describe a case series of patients with chronic dry eye submitted to partial punctual occlusion.


Eligibility criteria:
inclusion criteria: * sin and symptom of dry eye * use more than 4 times a day topic lubricant for the eye exclusion criteria: * ocular diseases other than dry eye * use of systemic drugs

Keywords: cornea dry eye lacrimal punctual occlusion lacrimal film ocular surface
internet obesity treatment enhanced with motivational interviewing

Conditions: Obesity

Summary: internet-based weight control programs have been shown effective in producing weight loss, but in-person delivery of behavioral weight control produces significantly greater weight loss than on-line delivery of the same program. motivational interviewing has been shown to increase weight loss when delivered as an adjunct to in-person weight loss programs but has not been examined in conjunction with web-based obesity treatment. therefore, the overall goal of this project is to determine if the addition of on-line motivational interviewing to a web-based group behavioral obesity treatment program will augment weight loss outcomes.

this randomized controlled trial is designed to determine whether weight losses in a group behavioral weight loss intervention conducted over the internet are increased with the inclusion of individual, online mi sessions. all participants will receive the same online 6-month group-based behavioral weight loss program followed by 12 months of weight maintenance. overweight and obese adults at two study sties (n=426) will be randomized to (1) internet intervention; or 2) internet intervention with individual mi sessions occurring at three month intervals on a fixed schedule (internet+mi-fixed). assessments will be conducted every six months and will include measures of body weight and height, diet and exercise behaviors, quality of life, adherence measures (eg., attendance, compliance with self-monitoring), social influence components, motivation, treatment satisfaction, demographic data and descriptive information regarding use of website components. a third arm was added for the final 3 intervention cohorts. all participants received the program as described above with the addition of motivational interviewing contingent on participants' attendance in classes.

Eligibility criteria:
inclusion criteria: * must be over 18 * must have a bmi between 18 and 50 * must live within 60 minutes driving distance of university of arkansas, little rock, ar, or university of vermont, burlington, vermont * must be able to walk for exercise exclusion criteria:

Keywords: obesity weight loss internet treatment motivational interviewing
practicing alternative techniques to heal from depression: the path-d study

Conditions: Major Depressive Disorder

Summary: this study is a randomized, controlled trial of mindfulness-based cognitive therapy (mbct) versus health-enhancement program (hep) for patients with treatment-resistant major depressive disorder (mdd). both arms of the study will continue to receive the standard medication management treatment as usual (tau) throughout the study. mbct is a new technique that has been found to be effective for prevention of relapse in individuals in complete recovery from depression. mbct is a group-based, 8-week intervention that uses mindfulness meditation as its core therapeutic ingredient. it teaches people to have a different relationship to depressive thoughts and feelings. this study will use an active condition called the health enhancement program (hep) which was specifically developed to serve as a comparison condition for mindfulness interventions. hep has been shown to decrease global stress levels and to increase perceived health. stress has been considered a contributor to depression. one hundred and seventy four patients with mdd who have failed two or more adequate antidepressant trials will be identified and randomly assigned to one of two groups: mbct+tau or hep+tau. all patients who enroll in the study will undergo follow-up assessments at 3, 6, 9 and 12 months following the intervention. a supplemental portion of the study will enroll 88 patients to undergo functional magnetic resonance imagining (fmri) scans immediately before and after treatment to better understand the neural pathways implicated in depression and those that may be affected through treatment.


Eligibility criteria:
inclusion criteria: dsm-iv tr diagnosis of major depression receiving medication management. adequate trial of 2 or more antidepressants (athf) for a minimum of 6 weeks (one of which at ucsf). hamilton depression rating scale 17 score ≥ 14 any ethnicity english speaking male or female no current psychotherapy (i.e. only medication management treatment) or plan to start new psychotherapy during mbct or hep exclusion criteria: bipolar disorder, obsessive compulsive disorder, schizophrenia, schizoaffective disorder, antisocial and borderline personality disorders, current eating disorder, pervasive development delay major depression with psychotic features active suicidality (per ham-d17 \> 1 on item 3) meditation practice once or more per week; yoga more than twice per week at study entry substance abuse disorder within 6 months cognitive disorder with mini mental status exam score \< 25 medical illness rated 4 on cumulative illness rating scale

Keywords: treatment-resistant depression, meditation, mindfulness
the effect of intermittent fasting on body composition in women with breast cancer

Conditions: Breast Cancer

Summary: the objective of this study is to evaluate intermittent fasting after the treatment of breast cancer with surgery and radiation therapy. all participants will either delay their first meal of the day or advance their last meal to achieve an approximate 16-18 hour fasting period four times per week. over six months, the innovative protocol will 1) assess adherence, and is expected to 2) improve body composition, quality of life and inflammatory and metabolic variables linked with outcomes after breast cancer treatment. the long-term goal of this project is to incorporate this dietary strategy as a standard component of care for breast cancer patients.


Eligibility criteria:
inclusion criteria: * biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast stage i-iii * completed any chemotherapy prior to initiation of the trial (adjuvant endocrine therapy is permitted) * bmi \> 25 kg/m2 or body fat% greater or equal to 31% * have a schedule amenable to nutrition and dietitian counseling described within the study protocol as determined by the treating radiation oncologist * have access to the internet and email with capability to join zoom calls exclusion criteria: * metastatic breast cancer * currently receiving chemotherapy * uncontrolled hypertension or diabetes, defined as systolic blood pressure over 149, diastolic blood pressure over 99, or hemoglobin a1c greater than 8.9. * diabetic condition requiring the usage of insulin

Keywords: intermittent fasting